|
CFL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
2.396300E-04 |
| Normal-vs-Stage3 |
1.25455201782643E-14 |
| Normal-vs-Stage4 |
1.67366120962242E-12 |
| Stage1-vs-Stage2 |
3.283900E-03 |
| Stage1-vs-Stage3 |
8.746400E-01 |
| Stage1-vs-Stage4 |
2.371600E-01 |
| Stage2-vs-Stage3 |
2.463300E-03 |
| Stage2-vs-Stage4 |
9.974600E-04 |
| Stage3-vs-Stage4 |
3.933000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.56707999999783E-05 |
| Normal-vs-Asian |
1.15840004255574E-10 |
| Caucasian-vs-AfricanAmerican |
7.243900E-02 |
| Caucasian-vs-Asian |
3.530800E-01 |
| AfricanAmerican-vs-Asian |
3.643400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
9.251600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.3882006655308E-11 |
| Normal-vs-Age(81-100Yrs) |
7.823600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.837000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.003220E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.985000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.023600E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.817400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.283200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.409700E-04 |
| Classical-VS-Follicular |
2.83679968404726E-10 |
| Classical-VS-Other |
9.273800E-01 |
| Classical-VS-Normal |
5.88418203051333E-15 |
| Tall-VS-Follicular |
1.67821312402339E-12 |
| Tall-VS-Other |
7.662400E-02 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
4.525600E-02 |
| Follicular-VS-Normal |
1.462240E-03 |
| Other-VS-Normal |
3.396700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.44089209850063E-16 |
| Normal-vs-N1 |
4.76285677564192E-14 |
| N0-vs-N1 |
3.391800E-02 |
|
|
